Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized, Single Dose, Two-period Crossover Study to Demonstrate Bioequivalence Between the Controlled Release Paroxetine Tablet (37.5 mg) Manufactured at Cidra and Mississauga

NCT00749359 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00749359
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00749359 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized, Single Dose, Two-period Crossover Study to Demonstrate Bioequivalence Between the Controlled Release Paroxetine Tablet (37.5 mg) Manufactured at Cidra and Mississauga
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Completed
Start date
July 7, 2008
Completion date
September 16, 2008
Enrollment
166 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

depressive disorder